Kaya O, Keskinkaya Z, Isik Mermutlu S, Oguz Kilic S, Cakir H
Infect Dis Clin Microbiol. 2024; 5(2):127-135.
PMID: 38633013
PMC: 10986702.
DOI: 10.36519/idcm.2023.192.
Railton J, Volonte M, Isoletta E, Bonelli A, Barruscotti S, Brazzelli V
Front Immunol. 2024; 15:1354729.
PMID: 38352875
PMC: 10861681.
DOI: 10.3389/fimmu.2024.1354729.
Maynard N, Armstrong A
Curr Dermatol Rep. 2023; 12(2):45-55.
PMID: 37304177
PMC: 10068706.
DOI: 10.1007/s13671-023-00385-w.
Komine M, Ansary T, Hossain M, Kamiya K, Ohtsuki M
Int J Mol Sci. 2022; 23(20).
PMID: 36293117
PMC: 9603600.
DOI: 10.3390/ijms232012260.
Gheisari M, Zahedi K, Tehranchinia Z, Moravvej H, Abdollahimajd F, Dadkhahfar S
Skin Appendage Disord. 2022; 8(3):195-199.
PMID: 35698587
PMC: 8805067.
DOI: 10.1159/000520422.
The role of gender, race, and ethnicity in psoriasis patients with COVID-19 infection: A cross-sectional study.
Nguyen C, Shwe S, Yale K, Ghigi A, Zheng K, Atanaskova Mesinkovska N
Int J Womens Dermatol. 2022; 8(1):e012.
PMID: 35369119
PMC: 8939651.
DOI: 10.1097/JW9.0000000000000012.
Novel Therapeutic Approaches to Psoriasis and Risk of Infectious Disease.
Motolese A, Ceccarelli M, Macca L, Li Pomi F, Ingrasciotta Y, Nunnari G
Biomedicines. 2022; 10(2).
PMID: 35203438
PMC: 8869084.
DOI: 10.3390/biomedicines10020228.
Management of Psoriasis During the Coronavirus Disease 2019 Pandemic.
Tan K, Encarnacion M, Marushchak O, Anvekar R
J Clin Aesthet Dermatol. 2022; 14(9):41-44.
PMID: 34980970
PMC: 8675334.
Updates on Management of Leprosy in the Context of COVID-19 Pandemic: Recommendations by IADVL SIG Leprosy.
Bhardwaj A, Gupta S, Narang T, Suneetha S, Pradhan S, Agarwal P
Indian Dermatol Online J. 2022; 12(Suppl 1):S24-S30.
PMID: 34976878
PMC: 8664173.
DOI: 10.4103/idoj.idoj_513_21.
COVID-19 and Dermatology in Iran.
Mansouri P, Farshi S, Nikkhah N, Najar Nobari N, Chalangari R, Nilforoushzadeh M
Clin Dermatol. 2021; 39(4):703-706.
PMID: 34809776
PMC: 8129800.
DOI: 10.1016/j.clindermatol.2021.05.022.
COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab.
Ungar B, Glickman J, Golant A, Dubin C, Marushchak O, Gontzes A
J Allergy Clin Immunol Pract. 2021; 10(1):134-142.
PMID: 34737108
PMC: 8558098.
DOI: 10.1016/j.jaip.2021.10.050.
COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea.
Baek M, Lee M, Kim W, Choi J, Jung S
PLoS One. 2021; 16(10):e0257641.
PMID: 34597325
PMC: 8486114.
DOI: 10.1371/journal.pone.0257641.
The Use of Biologics During the COVID-19 Pandemic.
Jones M, Kucharik A, Pourali S, Rajkumar J, Gutierrez Y, Yim R
Dermatol Clin. 2021; 39(4):545-553.
PMID: 34556244
PMC: 8166518.
DOI: 10.1016/j.det.2021.05.010.
Immunosuppressive and immunomodulatory therapies in dermatology and coronavirus disease 2019 (COVID-19).
Mansouri P, Farshi S, Nikkhah N, Najar Nobari N, Chalangari R, Nilforoushzadeh M
Clin Dermatol. 2021; 39(3):517-520.
PMID: 34518013
PMC: 7884222.
DOI: 10.1016/j.clindermatol.2021.01.003.
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses.
Fagni F, Simon D, Tascilar K, Schoenau V, Sticherling M, Neurath M
Lancet Rheumatol. 2021; 3(10):e724-e736.
PMID: 34485930
PMC: 8397302.
DOI: 10.1016/S2665-9913(21)00247-2.
Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence.
Piaserico S, Gisondi P, Cazzaniga S, Di Leo S, Naldi L
J Invest Dermatol. 2021; 142(2):355-363.e7.
PMID: 34363826
PMC: 8334343.
DOI: 10.1016/j.jid.2021.04.036.
Psoriasis-related treatment exposure and hospitalization or in-hospital mortality due to COVID-19 during the first and second wave of the pandemic: cohort study of 1 326 312 patients in France.
Penso L, Dray-Spira R, Weill A, Zureik M, Sbidian E
Br J Dermatol. 2021; 186(1):59-68.
PMID: 34310699
PMC: 8444811.
DOI: 10.1111/bjd.20659.
Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
Kridin K, Schonmann Y, Damiani G, Peretz A, Onn E, Tzur Bitan D
Dermatol Ther. 2021; 34(4):e15003.
PMID: 34033207
PMC: 8209905.
DOI: 10.1111/dth.15003.
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?.
Patsatsi A, Kyriakou A
Clin Dermatol. 2021; 39(1):52-55.
PMID: 33972053
PMC: 7834280.
DOI: 10.1016/j.clindermatol.2020.12.012.
Psoriasis care during the time of COVID-19: real-world data on changes in treatments and appointments from a German university hospital.
Ninosu N, Roehrich F, Diehl K, Peitsch W, Schaarschmidt M
Eur J Dermatol. 2021; 31(2):183-191.
PMID: 33871361
PMC: 8356542.
DOI: 10.1684/ejd.2021.4016.